From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: DCTA

Search articles by EPIC code
EPIC DCTA
views

Directa Plus – argues ‘proving to customers’… but what about demand & the balance sheet?...

“Successful Absorption Evaluation Test”-titled announcement from Directa Plus (DCTA) re. its pristine graphene nanoplatelets powder through human skin, with it stated “our suite of successful in vitro tests proves to customers in the textile industry that they can safely adopt our products to create exciting new garments enhanced by our graphene products”. Exciting news?...

EPIC DCTA
views

Directa Plus – argues trading “success”. Really?...

A trading update from Directa Plus (DCTA) includes that the company “finished 2020 with better revenues than expected even at the start of December” – and the shares have currently responded more than 13% higher, above 90p. But revenue is, of course, vanity and the achievement in ‘better than expected’, of course, depends on what the expectations are...

Page 3 of 4 (32 articles)
Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments